Compare
Propanc Biopharma, Inc. vs CytoDyn Inc. vs Tempest Therapeutics, Inc. vs Kala Bio, Inc.
| Latest fiscal year | Propanc Biopharma, Inc. PPCB | CytoDyn Inc. CYDY | Tempest Therapeutics, Inc. TPST | Kala Bio, Inc. KALA |
|---|---|---|---|---|
| Year ended | 2026-06-30 | 2026-05-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | n/a | $0 |
| Revenue growth (YoY) | n/a | n/a | n/a | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | n/a |
| Net margin | n/a | n/a | n/a | n/a |
| Net income | -$18.86M | -$42.70M | -$26.26M | -$26.98M |
| EPS (Diluted) | -$17.62 | -$0.03 | -$6.33 | -$3.31 |
| Operating cash flow | -$5.68M | -$17.25M | -$26.82M | -$31.99M |
| Free cash flow | -$5.69M | n/a | -$26.82M | n/a |
| Cash & equivalents | n/a | $11.85M | $7.71M | $7.56M |
| Total assets | $12.78M | $13.97M | $16.93M | $9.49M |
| Total liabilities | $3.38M | $123.69M | $10.26M | $2.49M |
| Shareholders' equity | $9.40M | -$109.72M | $6.67M | $7.00M |
| Return on year-end equity | -200.6% | n/a | -393.9% | -385.6% |
| Shares outstanding | 3.31M | 1.37B | 4.93M | 27.85M |
Revenue, most recent five fiscal years
| Fiscal year | Propanc Biopharma, Inc. | CytoDyn Inc. | Tempest Therapeutics, Inc. | Kala Bio, Inc. |
|---|---|---|---|---|
| Latest | n/a | $0 Ended 2023-05-31 | $295.0K Ended 2017-12-31 | $0 Ended 2025-12-31 |
| 1 year earlier | n/a | $266.0K Ended 2022-05-31 | $653.0K Ended 2016-12-31 | $0 Ended 2024-12-31 |
| 2 years earlier | n/a | $0 Ended 2021-05-31 | $277.0K Ended 2015-12-31 | $0 Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | $0 Ended 2014-12-31 | $3.89M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $0 Ended 2013-12-31 | $11.24M Ended 2021-12-31 |